|
Apr 11
|
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
|
|
Apr 11
|
Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
|
|
Apr 11
|
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
|
|
Apr 10
|
Why Janux Therapeutics Stock Soared as the Market Sagged Today
|
|
Apr 8
|
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)
|
|
Mar 28
|
Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know
|
|
Mar 22
|
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade
|
|
Mar 20
|
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst
|
|
Mar 15
|
2 Stocks That Have More Than Tripled This Year: Are They Buys?
|
|
Mar 8
|
Janux Therapeutics Inc (JANX) Reports Encouraging Clinical Data and Solid Financial Position ...
|
|
Mar 8
|
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
|
|
Mar 4
|
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
|
|
Dec 27
|
An Intrinsic Calculation For Janux Therapeutics, Inc. (NASDAQ:JANX) Suggests It's 44% Undervalued
|
|
Dec 1
|
Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?
|
|
Nov 10
|
Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Nov 7
|
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
|
|
Aug 10
|
Wall Street Analysts Think Janux Therapeutics, Inc. (JANX) Could Surge 120.82%: Read This Before Placing a Bet
|
|
Aug 8
|
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 8
|
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
|